{"disease":{"id":"osteomalacia","name":"Osteomalacia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"burosumab","indication_name":"Osteomalacia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crysvita","generic_name":"BUROSUMAB","company_name":"Ultragenyx Pharm Inc","drug_phase":"marketed","molecular_target":"FGF23","drug_class":"","quality_score":62,"revenue":"700","mechanism":"Burosumab-twza binds to and inhibits FGF23, restoring renal phosphate reabsorption and increasing 1,25 dihydroxy vitamin D levels."},{"drug_id":"falecalcitriol","indication_name":"Osteomalacia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hornel","generic_name":"FALECALCITRIOL","company_name":"Taisho Pharmaceutical","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"cholecalciferol","indication_name":"Osteomalacia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin D3","generic_name":"cholecalciferol","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Sterol 26-hydroxylase, mitochondrial","drug_class":"Vitamin C [EPC]","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"colecalciferol","indication_name":"Osteomalacia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"Colecalciferol","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"calciferol","indication_name":"Osteomalacia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"burosumab-twza","indication_name":"Osteomalacia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CRYSVITA","generic_name":"BUROSUMAB-TWZA","company_name":"KYOWA KIRIN","drug_phase":"marketed","molecular_target":"Fibroblast growth factor 23","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Osteomalacia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00024804","title":"A Natural History Study of Bone and Mineral Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT04841213","title":"Dental Implants Rehabilitation in Patients With Vitamin D3 Imbalance","phase":"NA","overall_status":"COMPLETED","enrollment_count":384,"lead_sponsor_name":"I.M. Sechenov First Moscow State Medical University","has_results":false},{"nct_id":"NCT06202027","title":"Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Kyowa Kirin Korea Co., Ltd.","has_results":false},{"nct_id":"NCT00001242","title":"Studies of States With Resistance to Vitamin D and Parathyroid Hormone","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT04045834","title":"Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04689893","title":"Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT00099762","title":"Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT07366099","title":"Al18F-NOTA-LM3 PET/CT in Patients With TIO","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05716750","title":"Serum Prolidase Activity and the Role of Leptin in Osteomalacia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":38,"lead_sponsor_name":"TUĞBA ŞAHBAZ","has_results":false},{"nct_id":"NCT04783428","title":"Tumor-induced Osteomalacia Disease Monitoring Program","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT03736564","title":"Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02304367","title":"Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT03233126","title":"A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT05357573","title":"Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT03510455","title":"BGJ398 for the Treatment of Tumor-Induced Osteomalacia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":true},{"nct_id":"NCT01748812","title":"Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT03775187","title":"Expanded Access to Burosumab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}